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The uremic toxin Indoxyl-3-sulphate (IS), a ligand of Aryl hydrocarbon Receptor (AhR),
raises in blood during early renal dysfunction as a consequence of tubular damage, which
may be present even when eGFR is normal or only moderately reduced, and promotes car-
diovascular damage and monocyte-macrophage activation. We previously found that
patients with abdominal aortic aneurysms (AAAs) have higher CD14+CD16+ monocyte fre-
quency and prevalence of moderate chronic kidney disease (CKD) than age-matched con-
trol subjects. Here we aimed to evaluate the IS levels in plasma from AAA patients and to
investigate in vitro the effects of IS concentrations corresponding to mild-to-moderate CKD
on monocyte polarization and macrophage differentiation.
Methods
Free IS plasma levels, monocyte subsets and laboratory parameters were evaluated on
blood from AAA patients and eGFR-matched controls. THP-1 monocytes, treated with IS 1,
10, 20 μMwere evaluated for CD163 expression, AhR signaling and then induced to differen-
tiate into macrophages by PMA. Their phenotype was evaluated both at the stage of semi-dif-
ferentiated and fully differentiated macrophages. AAA and control sera were similarly used to
treat THP-1 monocytes and the resulting macrophage phenotype was analyzed.
Results
IS plasma concentration correlated positively with CD14+CD16+ monocytes and was
increased in AAA patients. In THP-1 cells, IS promoted CD163 expression and transition to
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macrophages with hallmarks of classical (IL-6, CCL2, COX2) and alternative phenotype (IL-
10, PPARγ, TGF-β, TIMP-1), via AhR/Nrf2 activation. Analogously, AAA sera induced dif-
ferentiation of macrophages with enhanced IL-6, MCP1, TGF-β, PPARγ and TIMP-1
expression.
Conclusion
IS skews monocyte differentiation toward low-inflammatory, profibrotic macrophages and
may contribute to sustain chronic inflammation and maladaptive vascular remodeling.
Introduction
Renal and cardiovascular (CV) damage often coexist with mutual detrimental feedback. While
the presence of advanced chronic kidney disease (CKD) is an established risk factor for
increased CV morbidity and mortality [1], the cardiovascular burden attributable to mild CKD
is still underestimated and only partially characterized.
More recent is the assumption that renal function, traditionally evaluated by monitoring the
estimated glomerular filtration rate (eGFR), may be assessed and refined with circulating and
urinary biomarkers of tubular damage, because these markers are more sensitive and specific
than serum creatinine to early changes in renal function, retain predictive value and confer
independent excess risk for clinical outcomes as was shown in in patients with heart failure
(HF) [2].
Early during CKD progression, protein-bound compounds, normally cleared by healthy
kidneys, accumulate in blood and tissue. They are referred to as uremic toxins (UT) and exert
noxious effects on different cell types and organs, including the CV system.
One of the best studied UT is the organic anion indoxyl-3-sulfate (IS). In physiological con-
ditions, the circulating IS is cleared by renal proximal tubular secretion. In contrast, the total
amount of IS rises up to 500 μM and beyond in blood of uremic patients as a consequence of
tubular renal damage [3]. High IS concentrations participate in the development of both CKD
and CV disease (CVD) [4–6].
IS is an agonist of the Aryl-hydrocarbon receptor (AhR), a ligand-activated transcription
factor involved in the regulation of many biological functions [7,8,9]. In particular, AhR is
overexpressed during monocyte-to-macrophage transition; AhR signaling cross-talks with the
NF-E2p45-related factor 2 (Nrf2)-Heme Oxygenase-1 (HO1) pathway, which mediates antiox-
idant responses [10], and with the nuclear receptor Proliferator-Activated Receptor gamma
(PPARγ) [11,12], which has anti-inflammatory activity and is upregulated during macrophage
differentiation [13].
High IS levels, as found in end-stage CKD, have also been shown to affect monocyte/macro-
phage activation [14,15]. Remarkably, monocyte activation is implicated in the pathogenesis of
abdominal aortic aneurysm (AAA) [16,17].
We recently reported that patients with AAA frequently have mild-to-moderate CKD and
an expanded population of CD14+CD16+monocytes [18], which represent an intermediate
subset among the ‘classical’ (CD14+CD16-) and ‘nonclassical’ (CD14dimCD16+) ones. Mono-
cytes also express various scavenger receptors, including the membrane haemoglobin-hapto-
globin complex, CD163, which identifies a pool of monocytes more resistant to oxidative stress
[19]. In this paper, we initially measured IS levels in sera from AAA patients and eGFR
matched control subjects and analyzed their relationship with markers of inflammation and
monocyte subpopulations. Next, we characterized how IS at the concentrations found in early
stages of CKD, which is the condition observed in our AAA patients, impact on THP-1
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monocyte/macrophage differentiation; finally, as proof of concept that circulating factors asso-
ciated with AAAs modulate monocyte activation, the effects of IS and AAA sera on macro-
phage phenotypes were compared.
Material and Methods
Study population
This study was approved by the Ethics Committee of the University of Genoa, Italy, and
adhered to the Declaration of Helsinki Principles. We studied 45 patients undergoing elective
open repair of AAA, recruited at the Unit of Vascular and Endovascular Surgery of the San
Martino-IST hospital (Genoa, Italy) and 19 age-matched control subjects recruited from our
outpatient clinic. All study participants, selected on the basis of the criteria listed in Table A in
S1 File, gave their informed consent.
Laboratory assessment
Complete blood count and biochemical parameters were measured by means of standard tech-
niques at the Laboratory Unit of the San Martino-IST Hospital. The Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation was used to estimate the Glomerular Filtra-
tion Rate (eGFR) [20] and to categorize CKD stage as indicated in Table A in S1 File. Periph-
eral blood was centrifuged at 1710g for 15 minutes at 4°C and stored at -80°C for subsequent
assessment. Free IS was measured on plasma samples (Human Indoxyl Sulfate ELISA Kit,
MyBioSource, Inc. San Diego, CA USA).
Human monocyte phenotyping
Ficoll-isolated peripheral blood mononuclear cells (PBMCs) were immunostained with anti-
CD14 PE (clone RMO52; Beckman Coulter), and anti-CD16 PECy5 (clone 3G8; Biolegend)
antibodies. Monocytes were analysed by flow-cytometry (FACS calibur and CellQuest software
from Becton Dickinson). The CD14+CD16-, CD14+CD16+ and CD14dimCD16+ subsets were
identified as previously described [21].
The surface CD163 expression was detected with the anti-human CD163 FITC-conjugate
(clone GHI/61, Abcam); the intracellular AhR expression, was determined on cells permeabi-
lized with Fix-Perm (BD) by unconjugated anti-AhR antibody (clone RPT9, Abcam) labeled
with the green probe of Zenon Tricolor Mouse IgG1 Labeling Kit (Life technologies).
Cell culture
Monocyte THP-1 cell line was obtained from the European Collection of Cell Cultures
(ECACC) and maintained in complete culture medium (RPMI, 10% FBS, 2% Glutamine and
1% Penicillin/Streptomycin). Cells were treated with 1, 10, 20μM IS, that reflect mean IS values
found in humans with stage I, II and III CKD [22], diluted in ultrapure H2O. To hamper the
AhR activation, cells were treated with 10μMCH-223191 (CH), a selective AhR antagonist
(Figure A in S2 File), diluted in DMSO, according to the manufacturer’s instruction (Sigma)
and compared at different time points, on the basis of the experimental purposes. Cells were
also incubated in medium containing sera pooled from the two study populations, indicated as
AAA sera and Normal sera respectively (RPMI, 5% sera pooled from AAA patients or, alterna-
tively, from control subjects, 2% Glutamine and 1% Penicillin/Streptomycin).
After treatment, THP-1 cells were induced to differentiate into macrophages by incubation
in complete medium with 50 nM phorbol-myristate-acetate (PMA, Sigma) for 12 h; cells were
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then washed with PBS and kept in complete medium for further 3 (semi-differentiated macro-
phages M/2M), or 6 days (monocyte-derived macrophages, MdM).
Apoptosis and proliferation
Apoptosis and proliferation were evaluated by flow cytometry (FACSCanto II, BD Italia, Facs-
Diva software, BD) using Alexa Fluor 488 Annexin V/Dead Cell Apoptosis Kit (Life Technolo-
gies) and carboxyfluoresceinsuccinimidyl ester (CFDA-SE; Invitrogen, Milan, Italy) as
previously described [23], respectively. The Proliferation Wizard module of the ModFit LT 3.2
software (Verity Software House, Topsham, ME, USA) was used and the results were expressed
as percentage of cells in the first and second generation.
Expression of CD163 and CCR2
CD163 and CCR2 membrane expression was evaluated as median of cell fluorescence after
staining with anti-human CD163 FITC-conjugate (clone GHI/61, Abcam) and the anti-human
CCR2 Alexa Fluor 647 (clone 48607, Pharmingen). Cells were analyzed with FACS Calibur,
software Cell Quest, and FACSCanto II, software FACSDiva, respectively (BD, Italy).
ROS production
Intracellular ROS production was evaluated by the CellROX1 deep red kit from Life Technol-
ogies. Following treatments, CellROX1 Reagent was added for 30 minutes, then cells were
directly analyzed on FACSCanto II.
Chemotaxis
Migration assay was performed in Boyden chambers through polycarbonate polyvinylpyrroli-
done-free filters (5-nm pore size, Millipore). Five×105 cells were placed in the upper compart-
ment of the Boyden chamber and CCL2 (10 ng/ml) or PBS as negative control were placed in
the lower compartment. Cells were incubated at 37°C for 3 hours. The migrated cells on the
lower side of filters were fixed in ethanol, stained with toluidine blue (2%), and quantitated
microscopically at a 20x magnification. Five random fields were counted.
Confocal microscopy
Cells fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS, saturated
with 0.5% serum albumin in PBS and incubated overnight at 4°C with the following primary
antibodies: mouse monoclonal anti-AhR and rabbit polyclonal anti-AhRR (Abcam, UK).
Chicken anti-rabbit Alexa Fluor 633 or chicken anti-mouse Alexa Fluor 488 labelled were used
as secondary antibodies. Nuclei were counterstained with Propidium Iodide.
Images were collected by a three-channel TCS SP2 laser scanning confocal microscope
(Leica Wetzlar, Germany). Co-localization was analyzed through two-dimensional correlation
cytofluorograms accomplished by macro routines integrated as plugins in ImageJ 1.4 software
(Wayne Rasband, NIH, Bethesda, MD, USA).
cDNA reverse transcription and quantitative reverse transcription-PCR
Total RNA was extracted using TRIZOL reagent (Invitrogen) according to the manufacturer's
instructions. RNA (1 μg) was reverse-transcribed into cDNA by random hexamer primer and
SuperScript II Reverse Transcriptase (Invitrogen). Gene expression for NFE2L2 (Nrf2),
HMOX1 (HO1), AhR, AhRR and RPLP0 were performed with pre-designed primers Prime-
Time Mini qPCR Assay by IDT TemaRicerca (Italy), using the TaqMan Universal PCR Master
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Mix on a 7900HT Fast Real Time PCR System (Applied Biosystems). Results were normalized
to RPLP0 expression. Gene expression for CCR2, IL-6 and CCL2 was quantified using β-Actin
for the normalization. The corresponding primers were obtained from Primerdesign (South-
ampton, UK). PCR amplification was carried out using the SYBR Green solution Mastermix
on a Master Cycler Real Plex PCR system (Eppendorf, Hamburg, Germany) (Table B in S1
File). Assays were run in triplicate. The 2-ΔΔCT method of relative quantification was used to
determine the mRNA fold induction in IS-treated versus Control cells.
Western blotting
Cell were lysated in RIPA buffer and run on reducing SDS-acrylamide gels. Samples were elec-
trotransferred to PVDF, and the membranes were saturated at room temperature for 1 h, incu-
bated with primary antibodies overnight, and then with the corresponding horseradish
peroxidase-secondary antibodies (Santa Cruz) for 1 h at room temperature. The bands were
visualized by ECL chemiluminescence (Pierce). The membranes were stripped (20 min at
50°C) and re-blotted with GAPDH antibody. Bands were quantified by optical densitometry
(gel analysis system GeneGenius, Syngene, Cambridge, UK). Primary antibodies: mouse-
monoclonal anti-AhR (RPT9), rabbit- polyclonal AhRR, rabbit-polyclonal anti-PPARγ, mouse
monoclonal anti HO1 from Abcam; rabbit polyclonal anti-TGF-β from Cell Signaling; rabbit
polyclonal anti TIMP-1 from Chemicon; rabbit polyclonal GAPDH, rabbit polyclonal anti-
Nrf2, rabbit polyclonal anticytochrome P450-reductase (CYPOR) and rabbit polyclonal anti-
COX2 from Santa Cruz.
Zymography for MMP-9
Equivalent protein amounts from culture medium were loaded on SDS acrylamide gel cast
with 0.28% w/v gelatine (type A), run at 6–8°C in a water-cooled box, rinsed twice for 30 min,
incubated for 16–18h at 37°C with incubation buffer, stained and destained with the relative
buffers. Uncolored bands were quantified by optical densitometry (gel analysis system Gene-
Genius, Syngene, Cambridge, UK).
CCL2 and IL-10 quantification
IL-10 and CCL2 levels were measured in culture medium by Instant ELISA immunoassay
according to manufacturer instructions (BMS215INSTCE and MS281INSTCE, eBioscience).
Buffer Recipes
See Buffer Recipes in S1 File.
Statistical analysis
Continuous clinical and laboratory parameters are presented as mean±SD or median (inter-
quartile range) depending on their normal or skewed distribution. Comparisons were drawn
by t-test, Mann-Whitney test, Chi-square test as appropriate. The relationship between IS con-
centrations and selected variables was examined by means of the Pearson (for normally distrib-
uted data) or Spearman (for skewed data distributions) correlation test. In vitro experiments
were performed at least 3 times; data are given as mean ± SEM and were compared by Student’s
t test and ANOVA. Statistical significance was set at p<0.05. All statistical analyses were per-
formed using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, Cali-
fornia, USA.
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Results
Levels of free IS and correlation with eGFR and monocyte subsets in
blood of AAA patients and Control subjects
Since IS accumulates in the blood during early renal dysfunction, both as albumin-bound and
free fraction, we compared the concentrations of free IS, which is the biologically active form,
between AAA patients and control subjects selected for having a similar eGFR (74.95± 2.35 vs.
73.73±2.9,mean ±SEM; p = NS). When compared to control subjects, AAA patients had signif-
icantly higher levels of free IS (18.5±0.62 nM vs. 14.43±1.39 nM, mean±SEM; p = 0.004) (Fig
1A; Table C in S1 File) and of D-dimer [18] (Table D in S1 File).
In the total study population, IS correlated positively with the percentage of circulating
CD14+CD16+monocytes (p = 0.015, r = 0.3) (Fig 1B) and negatively with eGFR (0.039)
(Table E in S1 File). Interestingly, when separately considering AAA patients and control sub-
jects, IS was inversely related to eGFR only in control subjects (p = 0.02, r = -0.5425), while
there was no association in AAA patients (Fig 1C and 1D).
AhR was more expressed in CD16+monocytes than in CD16-monocytes, the highest levels
being in CD14+CD16+monocytes (Figure B-A in S2 File). Consistent with previous reports
[24], also CD163 was maximally expressed by CD14+CD16+monocytes, while its levels were
Fig 1. Free IS levels, CD14+CD16+ monocytes and eGFR in study populations. (A) IS serum levels in
AAA patients versus age- and e-GFR-matched control subjects, **p<0.01; (B) scattergram and regression
line representing the relationship of CD14+CD16+monocyte percentages with IS serum levels (p = 0,014;
r = 0,34); (C) and (D): scattergram and regression line representing the relationship between IS
concentrations and eGFR in control subjects (empty circle, p = 0,02; r = -0,55) and AAA patients (grey
triangle, p = 0,2; r = -0,17) respectively.
doi:10.1371/journal.pone.0149276.g001
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lower in CD14+CD16-cells and barely detectable in theCD14dimCD16+subset (Figure B-B in S2
File).
AhR-dependent effect of IS on CD163 expression in THP-1 monocytes
IS upregulated CD163 expression in a concentration- and time-dependent manner: after 48
hours, 1, 10, and 20 μM IS induced, respectively, a 1.5, 2.5 and 2.8-fold increase in CD163 ver-
sus control; after 72 hours, CD163 levels were increased 2.3, 2.5 and 2.9 times respectively ver-
sus control (Fig 2A). CD163 induction was counteracted by the AhR antagonist CH,
confirming that IS effect was AhR-mediated (Fig 2A).
Effects of IS on THP-1 monocyte viability, ROS production, and
proliferation
Cell incubation with IS ± the AhR-antagonist CH did not significantly change the apoptotic
rate compared to control cells (Figure C-A in S2 File). Cell incubation with 1, 10, 20 μM IS
transiently increased the ROS production at 30 minutes (respectively 268 ± 18%, 177 ± 26%,
239 ± 36%, vs. untreated cells, p<0,05), although values were significantly lower than those
obtained after exposure to1mM IS (464+ 31%vs. untreated cells, p<0.001) which corresponds
to the maximal uremic concentration [3] and was used as positive control. After 45 minutes,
only 1mM IS treated cells displayed an increased ROS production compared to control cells
(p<0.001). No significant differences between IS-treated and control cells were observed at
longer incubation times (Figure C-B in S2 File). Treatment with IS for 72 hours significantly
reduced cell proliferation, as revealed by the percentage of cells in the second generation. In
contrast, pre-treatment with CH dramatically increased the proliferation rate compared to
control cells (Fig 2B).
IS induces CCL2 dependent migration of THP-1 monocytes
Cells treated for 48 h with IS were allowed to migrate toward a CCL2 gradient in a Boyden
chamber for 3 h. Chemotaxis induced by CCL2 was increased after treatment with 20 μM IS
and effectively counteracted by pre-treatment with CH (Fig 2C).
The increased migratory rate was not attributable to an enhanced expression of the CCL2
receptor CCR2, since its membrane expression was not affected by IS/CH treatment (Fig 2D).
Rather, we found that CCR2 was significantly down regulated as gene expression after a 10 and
20 μM IS treatment (Fig 2E). Therefore, we believe that IS-induced migratory activity could be
ascribed to a cell commitment in monocyte-to-macrophage transition, as confirmed by the
dramatic increase in CCL2 transcript levels (Fig 2F), a phenomenon already described [25].
AhR/AhRR ratio in IS-treated THP-1 monocytes
The cell responses induced by ligand-activated AhR are counteracted by the AhR Repressor
(AhRR), which translocates to the nucleus and inhibits AhR. This feedback loop was main-
tained in THP-1 monocytes exposed to IS: indeed, IS treatment for 72 hours increased the
nuclear localization of both AhR and AhRR in a concentration-dependent manner (Fig 2G).
AhRR dampens AhR-dependent activation of xenobiotic metabolizing enzymes such as cyto-
chrome p450. We evaluated the net activity resulting from the ratio AhR/AhRR by considering
the protein expression of cytochrome p450 reductase (CYPOR), an electron donor that is a
substrate for cytochrome p450. CYPOR was decreased in 10 and 20 μM IS treated cells (37 +
16 and 47 + 25% respectively), indicating that the cells are in a metabolic stressed status (Fig
2H).
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Fig 2. Effects of IS on THP-1 monocytes. Effect of 72 h treatment with 1, 10, 20 μM IS ±10 μMCH-223191 pretreatment (dashed bars) on (A) CD163
expression; § p< 0,05; **p< 0,01 vs. CTR; ***p<0,001 vs. CTR; (B) Proliferation rate expressed as % of cells in first (grey bars) and second (white bars)
generation as evaluated by flow cytometry using the CFSE-DA probe; *p<0.05 vs. IS1; **p<0.01 vs. CTR; #p<0.01 vs. the corresponding IS alone
IS Induces Profibrotic Macrophage Differentiation
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Effects of IS on the macrophage differentiation of THP-1 cells
THP-1 cells treated with IS for 72 h were stimulated with PMA to differentiate into macro-
phages. IS-primed M/2Mmacrophages displayed an upregulation of theAhR/Nrf2 pathways:
the gene expression was modestly enhanced for AhR (30% and 60% in M/2M treated, respec-
tively, with 10μM and 20 μM IS vs. control), AhRR (about 50% increase at the three concentra-
tions vs. control), Nrf2 (about a 50% increase vs control with 10 and 20 μM IS) and HO-1 (a
50% increase vs control for 10 and 20 μM IS) (Fig 3A–3D). AhR activation leads to overexpres-
sion of inflammatory cytokines such as IL-6 and CCL2 [26,27]. In our conditions, the IL-6
concentrations; (C) Chemotaxis during 3 hours of incubation in a Boyden chamber after a 48 h IS treatment; CCL2 (10 ng/ml) and PBS were used as
chemoattractant and negative control respectively. Values are expressed by means of cell number/field on a polycarbonate polyvinylpyrrolidone-free filter
(5-nm pore size). *p<0.05; § p<0.05; #p<0.05 vs 20μM IS. (D) CCR2membrane expression in cells after 72 h IS treatment evaluated by flow cytometry. (E)
CCR2 and (F) CCL2 gene expression in cells after 24 h IS treatment as revealed by RT-PCR; **p< 0,01; ***p<0,001 vs. CTR. Results are plotted as mRNA
fold induction (mean ± SEM) versus control cells.(G) Immunofluorescence localization of AhR (green) and AhRR (blue) after a 72 hour IS treatment; nuclei
are counterstained with Propidium Iodide (red). (H) Protein expression of CYPOR (cytochrome p450 reductase); * p <0.05; ** p <0.01 vs. CTR.
doi:10.1371/journal.pone.0149276.g002
Fig 3. Gene expression in IS-treated M/2M. RT-PCR for (A) AhR, (B) AhRR, (C) Nrf2, (D) HO1, (E) IL-6 and
(F) CCL2. Results were plotted as mRNA fold induction in IS-treated versus Control cells; * p <0.05;
** p <0.01; ***p<0,001 vs. control cells.
doi:10.1371/journal.pone.0149276.g003
IS Induces Profibrotic Macrophage Differentiation
PLOS ONE | DOI:10.1371/journal.pone.0149276 February 29, 2016 9 / 17
gene expression was increased in 10 and 20 μM IS-treated M/2Mmacrophages, with the high-
est levels observed in 10 μM IS-treated cells (Fig 3E). Similarly, CCL2 RNA transcript was dra-
matically upregulated in 10 and 20 μM IS-treated M/2Mmacrophages (Fig 3F).
Monocyte-derived-macrophages (MdM) were obtained after further 3 days of incubation.
Compared to control MdM, 10 and 20 μM IS-primed-MdM exhibited higher AhR and AhRR
expression (Fig 4A and 4B). Accordingly, CYPOR was down-regulated by IS treatment (Fig
4C). Of the Nfr2/ HO1/PPARγ signaling pathway, only the expression of latter was upregulated
by IS (Fig 4D–4F). Other two fibrogenic mediators, TGF-β and TIMP-1, were up-regulated by
IS (Fig 4G and 4H). Furthermore, IS primed MdM had a reduced activity of MMP-9 and an
enhanced secretion of IL-10 (Fig 4I and 4J).On the other hand, IS increased the CCL2 release
and the protein expression of COX2, a marker of proinflammatory macrophage differentiation
(Fig 4K and 4L).
Effects of Sera from AAA patients and control subjects on macrophage
differentiation of THP-1 cells
THP-1 cells were stimulated with PMA to differentiate into macrophages after a 72 hour incu-
bation in medium containing sera pooled from the 2 study groups. AAA sera, compared to
control-sera, dramatically enhanced the gene expression of IL-6 (p = 0,0016) and CCL2
(p = 0,0025) in M/2M (Fig 5A and 5B). In MdM, AAA sera increased PPARγ, TGF-β and
TIMP-1 total proteins, consistent with a profibrotic immune response, while reduced the
CYPOR expression (Fig 5C–5F).
Discussion
The main finding of our study is that a moderate increase of IS, as found during transition
from mild to moderate kidney damage, promotes monocyte differentiation towards macro-
phages with low-inflammatory, profibrotic potential.
We also demonstrated that free IS, the biologically active fraction, is higher in AAA patients
than control subjects matched for age and eGFR levels, correlates with the percentage of the
CD14+CD16+ monocyte subset, whose frequency is increased in CKD [28] and other chronic
inflammatory diseases, including AAA [18]. CD14+CD16+monocytes have a proinflammatory,
senescent phenotype [29], differentiate into tissue macrophages and have the highest expres-
sion of CD163. CD163 participates to the Nrf2-HO1 signaling [30,31] and, by modulating
HO1 expression, is indirectly linked to IL-10 production [32].
IS is one of the most investigated UT for its negative impact on the CV system. Clinical
studies have demonstrated that IS serum levels are a powerful predictor of overall and cardio-
vascular mortality [33].
IS at uremic concentration (100–500 μM) exerts multiple detrimental and proinflammatory
effects. To name a few, IS induces fibrosis in renal tubular cells, mesangial cells and aortic
smooth muscle cells; IS also increases the macrophage responsiveness to LPS and the activation
of monocytes through a ROS-production mediated mechanism [34,14], Nrf2 downregulation
[35] and induces tissue factor expression in monocytes and endothelial cells [15].
IS is a potent AhR ligand [36]. Alteration of the AhR signaling plays a causative role in
chronic inflammatory conditions [37,38]; the equilibrium between AhR and its repressor
(AhRR), rather than the induction of AhR expression, establishes the AhR contribution to cell
responses [39].
In our experimental conditions, we showed that IS activates the AhR/AhRR and Nrf2/HO1
pathways and arrests cell proliferation, an event associated to monocyte/macrophage transition
[40]. IS treated THP-1 monocytes have increased CD163 expression and accelerated
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Fig 4. Protein expression in IS treated MdM.Western Blot analysis of total cell lysates for (A) AhR, (B) AhRR, (C) CYPOR, (D) Nrf2, (E) HO1,(F) PPARγ,
(G) TGF-β, (H) TIMP-1, (I) COX2; values are normalized to GAPDH expression. (J) Gelatinolic activity of MMP-9. (K) IL-10 and (L) CCL2 content in IS-treated
MdM conditioned medium. * p <0.05; ** p <0.01; *** p <0.001 vs. CTR.
doi:10.1371/journal.pone.0149276.g004
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Fig 5. Gene and protein expression in M/2M and MdM treated with sera from AAA patients and control
subjects. RT-PCR for (A) IL-6, and (B) CCL2 in M/2M; results were plotted as mRNA fold induction in cell
treated with AAA sera vs. cells treated with Normal sera. Western Blot analysis of total cell lysates for (C)
IS Induces Profibrotic Macrophage Differentiation
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chemotaxis toward a gradient of CCL2, a redox-dependent phenomenon reported in metaboli-
cally stressed monocytes [41]. These effects indicate a priming toward an alternative phenotype
[42] which is counteracted by the AhR antagonist CH.
Upon PMA stimulation, IS primed THP-1 monocytes differentiate into macrophages with
upregulated activation of AhR and features of both alternative (reduction of MMP-9 activity,
overexpression of PPARγ, TIMP-1, TGF-β and IL-10) and classical (increased production of
IL-6, CCL2 and COX2) immune response (Fig 6).
We believe that PPARγ activation may be responsible for the reduced transcription of
inflammatory response genes, the upregulation of CD163 [43] and the modulation of the M1/
M2 macrophage transition [44].
On the contrary, increased COX2 expression is considered at large as a marker of classical
immune polarization. However, during inflammatory resolution, COX2 has been found to be
upregulated even in IL-10-producing macrophages [45]. These observations remind us how
macrophages retain various phenotypes associated to different inflammatory conditions.
So far, the presence of a mixed immune response, which is M2-like by surface marker
expression but competent to produce extensive amounts of inflammatory cytokines, has been
reported to be tissue- or site-specific, as observed for M2 macrophages infiltrating adipose tis-
sue in obesity [46], for macrophages in the intestinal lamina propria [47] and in animal model
of lung-specific IL-10 overexpression [48].
In this work, the highest levels of IL-6, CCL2 gene expression and IL-10 release and the low-
est transcript levels of CCR2, which reflects monocyte maturation [25], have been observed
after treatment with IS at concentrations found in subjects with moderate renal dysfunction.
The clinical relevance of this work may reside on the novel characterization of patients’ pop-
ulations at increased risk for major CV events and having mild to moderate renal dysfunction
on the basis of free IS levels. Indeed, eGFR was not different between AAA patients and control
subjects, while the two study groups differ for IS levels. Furthermore, eGFR did not contribute
and did not predict IS levels within the AAA subgroup of study patients. There may be several
explanations for these findings. AAA patients have a high prevalence of renal artery stenosis
[49] that promotes hypoxic tubular damage and makes the kidneys of these patients more vul-
nerable to hemodynamic changes and to ischemic and neurohormonal damage. Local and cir-
culating proinflammatory milieu associated to AAA may trigger tubular damage and lead to
impaired tubular cell function [50,51].
Chronic renal hypoxia associated to stenosis may also link tubular damage to interstitial
fibrosis and inflammation. AAA patients frequently undergo repeated use of nephrotoxic con-
trast agents for computed tomography/magnetic resonance techniques [52].
To our knowledge this study is the first to evidence that free IS at levels found in subclinical
renal dysfunction induce the differentiation of profibrotic macrophages. This process, by trig-
gering a feed-forward system of vascular cell activation upon local release of CCL2 and TGF-β,
may contribute to chronic inflammation and vascular remodeling [53].
In the clinical setting of patients with advanced AAA, increased IS levels may represent a
mechanism that promotes recruitment of profibrotic macrophages into the aortic wall and
other vessel districts, according to the homing sites of primed monocytes. Future studies
should address the clinical applicability of strategies to reduce circulating IS levels to hamper
arterial wall degeneration and organ damage.
PPARγ, (D) TGF-β, (E) TIMP-1 and (F) CYPOR in MdM; values are normalized to GAPDH expression.
* p <0.05; ** p <0.01 vs. CTR.
doi:10.1371/journal.pone.0149276.g005
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Limitation of the study
Monocyte cell lines might not fully reflect the behavior of human monocytes. However multi-
ple pathways (i.e. AhR, Nrf2, PPARγ) of IS activity may be already primed in monocytes from
healthy donors by, for instance, smoking habit [13], affecting the final response. Therefore, to
avoid the confounding effects of the inter-donors variability, we performed the in vitro study
using THP-1 and RAW 264.7 cells.
Concentrations of total IS are highly different from the concentrations of free plasma IS
fraction, and the proportion between total IS and its free active form may vary for several rea-
sons [3,54]. Thus, in the experimental plan we used the average values of total IS plasma levels






Fig 6. Proposed scheme of IS effects onmonocyte differentiation.Mild IS concentrations (1, 10, 20 μM)
potentiate the detoxifying and anti-oxidant pathways of AhR and Nrf2 in monocytes (THP-1 cells), resulting in
CD163 and HO1 overexpression and monocyte activation. Macrophages derived from IS-treated monocytes
(IS-treated MdM) retain an upregulation of the AhR activity and features of a profibrotic, low inflammatory
phenotype.
doi:10.1371/journal.pone.0149276.g006
IS Induces Profibrotic Macrophage Differentiation
PLOS ONE | DOI:10.1371/journal.pone.0149276 February 29, 2016 14 / 17
Author Contributions
Conceived and designed the experiments: C. Barisione SG MN GG. Performed the experi-
ments: C. Barisione SG ALF MND. Palmieri MP AG DV AP P. Altieri PFF. Analyzed the data:
C. Barisione SG ALF MP AG DV AP P. Altieri PF PFF MB D. Palombo GG. Contributed
reagents/materials/analysis tools: MN D. Palmieri MP AG DV AP PF PFF C. Brunelli D.
Palombo GG. Wrote the paper: C. Barisione SG MN P. Ameri VAMB GG.
References
1. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, et al. Mild renal insufficiency is asso-
ciated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62:1402–1407.
PMID: 12234312
2. Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, et al. Clinical outcome of renal
tubular damage in chronic heart failure. Eur Heart J 2011; 32:2705–2712. doi: 10.1093/eurheartj/
ehr190 PMID: 21666249
3. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, et al. European Uremic Toxin
Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual vari-
ability. Kidney Int 2003; 63:1934–1943. PMID: 12675874
4. Barisione C, Ghigliotti G, Canepa M, Balbi M, Brunelli C, Ameri P. Indoxyl sulfate: a candidate target for
the prevention and treatment of cardiovascular disease in chronic kidney disease. Curr Drug Targets
2015; 16:366–72. PMID: 25537654
5. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H. Does indoxyl sulfate, a uraemic
toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31:1771–9. doi: 10.
1093/eurheartj/ehp574 PMID: 20047993
6. TangWH,Wang CP, Chung FM, Huang LL, Yu TH, HungWC, et al. Uremic retention solute indoxyl sul-
fate level is associated with prolonged QTc interval in early CKD patients. PLoS One 2015; 10:
e0119545 doi: 10.1371/journal.pone.0119545 PMID: 25893644
7. Schroeder JC, Dinatale BC, Murray IA, Flaveny CA, Liu Q, Laurenzana EM, et al. The uremic toxin 3-
indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry
2010; 49:393–400. doi: 10.1021/bi901786x PMID: 20000589
8. Platzer B, Richter S, Kneidinger D, Waltenberger D, Woisetschläger M, Strobl H. Aryl hydrocarbon
receptor activation inhibits in vitro differentiation of human monocytes and Langerhans dendritic cells. J
Immunol 2009; 183:66–74. doi: 10.4049/jimmunol.0802997 PMID: 19535631
9. Gasiewicz TA, Singh KP, Casado FL. The aryl hydrocarbon receptor has an important role in the regu-
lation of hematopoiesis: implications for benzene-induced hematopoietic toxicity. Chem Biol Interact
2010; 184:246–251. doi: 10.1016/j.cbi.2009.10.019 PMID: 19896476
10. MiaoW, Hu L, Scrivens PJ, Batist G. Transcriptional regulation of NF-E2 p45-related factor (NRF2)
expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct
cross-talk between phase I and II drug-metabolizing enzymes. J Biol Chem 2005; 280:20340–20348.
PMID: 15790560
11. Medjakovic S, Mueller M, Jungbauer A. Potential health-modulating effects of isoflavones and metabo-
lites via activation of PPAR and AhR. Nutrients 2010; 2:241–279. doi: 10.3390/nu2030241 PMID:
22254019
12. Polvani S, Tarocchi M, Galli A. PPARγ and Oxidative Stress: Con(β) Catenating NRF2 and FOXO.
PPAR Res 2012; 2012:641087. doi: 10.1155/2012/641087 PMID: 22481913
13. Amoruso A, Bardelli C, Gunella G, Fresu LG, Ferrero V, Brunelleschi S. Quantification of PPAR-
gamma protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct
effect of nicotine. Life Sci 2007; 81:906–915. PMID: 17765929
14. Ito S, Higuchi Y, Yagi Y, Nishijima F, Yamato H, Ishii H, et al. Reduction of indoxyl sulfate by AST-120
attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol 2013; 93:837–845.
doi: 10.1189/jlb.0112023 PMID: 23362306
15. Gondouin B, Cerini C, Dou L, Sallée M, Duval-Sabatier A, Pletinck A, et al. Indolic uremic solutes
increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney
Int 2013; 84:733–744. doi: 10.1038/ki.2013.133 PMID: 23636172
16. Rateri DL, Howatt DA, Moorleghen JJ, Charnigo R, Cassis LA, Daugherty A. Prolonged infusion of
angiotensin II in apoE(-/-) mice promotes macrophage recruitment with continued expansion of abdomi-
nal aortic aneurysm. Am J Pathol 2011; 179:1542–1548. doi: 10.1016/j.ajpath.2011.05.049 PMID:
21763672
IS Induces Profibrotic Macrophage Differentiation
PLOS ONE | DOI:10.1371/journal.pone.0149276 February 29, 2016 15 / 17
17. Kaneko H, Anzai T, Takahashi T, Kohno T, Shimoda M, Sasaki A, et al. Role of vascular endothelial
growth factor-A in development of abdominal aortic aneurysm. Cardiovasc Res 2011; 91:358–67. doi:
10.1093/cvr/cvr080 PMID: 21436157
18. Ghigliotti G, Barisione C, Garibaldi S, Brunelli C, Palmieri D, Spinella G, et al. CD16(+) monocyte sub-
sets are increased in large abdominal aortic aneurysms and are differentially related with circulating
and cell-associated biochemical and inflammatory biomarkers. Dis Markers 2013; 34:131–142. PMID:
23348634
19. Boyle JJ, Harrington HA, Piper E, Elderfield K, Stark J, Landis RC, et al. Coronary intraplaque hemor-
rhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol 2009; 174:1097–1108.
doi: 10.2353/ajpath.2009.080431 PMID: 19234137
20. Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, et al. Comparative performance
of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease
(MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 2010;
56:486–95. doi: 10.1053/j.ajkd.2010.03.026 PMID: 20557989
21. Barisione C, Garibaldi S, Ghigliotti G, Fabbi P, Altieri P, Casale MC, et al. CD14CD16 monocyte subset
levels in heart failure patients. Dis Markers 2010; 28:115–124. doi: 10.3233/DMA-2010-0691 PMID:
20364047
22. Lin CJ, Chen HH, Pan CF, Chuang CK, Wang TJ, Sun FJ, et al. p-Cresylsulfate and indoxyl sulfate
level at different stages of chronic kidney disease. J Clin Lab Anal 2011; 25:191–197. doi: 10.1002/jcla.
20456 PMID: 21567467
23. Urbani S, Caporale R, Lombardini L, Bosi A, Saccardi R. Use of CFDA-SE for evaluating the in vitro pro-
liferation pattern of humanmesenchymal stem cells. Cytotherapy 2006; 8:243–253. PMID: 16793733
24. Shantsila E, Wrigley B, Tapp L, Apostolakis S, Montoro-Garcia S, Drayson MT, et al. Immunophenoty-
pic characterization of humanmonocyte subsets: possible implications for cardiovascular disease
pathophysiology. J Thromb Haemost 2011; 9:1056–66 doi: 10.1111/j.1538-7836.2011.04244.x PMID:
21342432
25. Phillips RJ, Lutz M, Premack B. Differential signaling mechanisms regulate expression of CC chemo-
kine receptor-2 during monocyte maturation. J Inflamm (Lond) 2005; 31:2–14.
26. DiNatale BC, Schroeder JC, Francey LJ, Kusnadi A, Perdew GH. Mechanistic insights into the events
that lead to synergistic induction of interleukin 6 transcription upon activation of the aryl hydrocarbon
receptor and inflammatory signaling. J BiolChem 2010; 285:24388–97.
27. Majkova Z, Smart E, Toborek M, Hennig B. Up-regulation of endothelial monocyte chemoattractant pro-
tein-1 by coplanar PCB77 is caveolin-1-dependent. Toxicol Appl Pharmacol 2009; 237:1–7. doi: 10.
1016/j.taap.2009.02.016 PMID: 19265715
28. Rogacev KS, Seiler S, Zawada AM, Reichart B, Herath E, Roth D, et al. CD14++CD16+ monocytes
and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011; 32:84–92. doi:
10.1093/eurheartj/ehq371 PMID: 20943670
29. Merino A, Buendia P, Martin-Malo A, Aljama P, Ramirez R, Carracedo J. Senescent CD14+CD16+
monocytes exhibit proinflammatory and proatherosclerotic activity. J Immunol 2011; 186:1809–1815.
doi: 10.4049/jimmunol.1001866 PMID: 21191073
30. Polfliet MM, Fabriek BO, Daniëls WP, Dijkstra CD, van den Berg TK. The rat macrophage scavenger
receptor CD163: expression, regulation and role in inflammatory mediator production. Immunobiology
2006; 211:419–425. PMID: 16920481
31. Boyle JJ, Johns M, Lo J, Chiodini A, Ambrose N, Evans PC, et al. Heme induces hemeoxygenase 1 via
Nrf2: role in the homeostatic macrophage response to intraplaque hemorrhage. Arterioscler Thromb
Vasc Biol 2011; 31:2685–2691. doi: 10.1161/ATVBAHA.111.225813 PMID: 21868703
32. Ugocsai P, Barlage S, Dada A, Schmitz G. Regulation of surface CD163 expression and cellular effects
of receptor mediated hemoglobin-haptoglobin uptake on humanmonocytes and macrophages. Cytom-
etry A 2006; 69:203–205. PMID: 16479607
33. Lin CJ, Pan CF, Liu HL, Chuang CK, Jayakumar T, Wang TJ, et al. The role of protein-bound uremic
toxins on peripheral artery disease and vascular access failure in patients on hemodialysis. Atheroscle-
rosis 2012; 225:173–9. doi: 10.1016/j.atherosclerosis.2012.07.012 PMID: 22981405
34. Adesso S, Popolo A, Bianco G, Sorrentino R, Pinto A, Autore G, et al. The uremic toxin indoxyl sulphate
enhances macrophage response to LPS. PLoS One 2013; 30:e76778.
35. Bolati D, Shimizu H, Yisireyili M, Nishijima F, Niwa T. Indoxyl sulfate, a uremic toxin, downregulates
renal expression of Nrf2 through activation of NF-κB. BMCNephrol 2013; 4:14:56.
36. Watanabe I, Tatebe J, Namba S, Koizumi M, Yamazaki J, Morita T. Activation of aryl hydrocarbon
receptor mediates indoxyl sulfate-induced monocyte chemoattractant protein-1 expression in human
umbilical vein endothelial cells. Circ J 2013; 77:224–230. PMID: 23037589
IS Induces Profibrotic Macrophage Differentiation
PLOS ONE | DOI:10.1371/journal.pone.0149276 February 29, 2016 16 / 17
37. Arsenescu V, Arsenescu R I, King V, Swanson H, Cassis LA. Polychlorinated biphenyl- 77 induces adi-
pocyte differentiation and proinflammatory adipokines and promotes obesity and atherosclerosis. Envi-
ron Health Perspect 2008; 116:761–768. doi: 10.1289/ehp.10554 PMID: 18560532
38. Arsenescu R, Arsenescu V, Zhong J, Nasser M, Melinte R, Dingle RW, et al. Role of the xenobiotic
receptor in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:1149–1162. doi: 10.1002/ibd.
21463 PMID: 20878756
39. Evans BR, Karchner SI, Allan LL, Pollenz RS, Tanguay RL, Jenny MJ, et al. Repression of aryl hydro-
carbon receptor (AHR) signaling by AHR repressor: role of DNA binding and competition for AHR
nuclear translocator. Mol Pharmacol 2008; 73:387–98. PMID: 18000031
40. Figarola JL, Weng Y, Lincoln C, Horne D, Rahbar S. Novel dichlorophenyl urea compounds inhibit pro-
liferation of human leukemia HL-60 cells by inducing cell cycle arrest, differentiation and apoptosis.
Invest New Drugs 2012; 30:1413–1425. doi: 10.1007/s10637-011-9711-8 PMID: 21728022
41. Ullevig S, Zhao Q, Lee CF, Seok Kim H, Zamora D, Asmis R. NADPH oxidase 4 mediates monocyte
priming and accelerated chemotaxis induced by metabolic stress. Arterioscler Thromb Vasc Biol 2012;
32:415–26. 30. doi: 10.1161/ATVBAHA.111.238899 PMID: 22095986
42. Shantsila E, Tapp LD, Wrigley BJ, Pamukcu B, Apostolakis S, Montoro-García S, et al. Monocyte sub-
sets in coronary artery disease and their associations with markers of inflammation and fibrinolysis. Ath-
erosclerosis 2014; 234:4–10. doi: 10.1016/j.atherosclerosis.2014.02.009 PMID: 24583499
43. Bähr IN, Tretter P, Krüger J, Stark RG, Schimkus J, Unger T, et al. High-dose treatment with telmisartan
induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the meta-
bolic syndrome. Hypertension 2011; 58:725–732. doi: 10.1161/HYPERTENSIONAHA.111.173542
PMID: 21876071
44. Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, et al. PPARgamma activation
primes humanmonocytes into alternative M2macrophages with anti-inflammatory properties. Cell
Metab 2007; 6:137–143. PMID: 17681149
45. Bystrom J, Evans I, Newson J, Stables M, Toor I, van Rooijen N, et al. Resolution-phase macrophages
possess a unique inflammatory phenotype that is controlled by cAMP. Blood 2008; 112:4117–4127.
doi: 10.1182/blood-2007-12-129767 PMID: 18779392
46. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Györi G, et al. Human adipose tissue macro-
phages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator pro-
duction. Int J Obes (Lond) 2007; 31:1420–1428.
47. Takada Y, Hisamatsu T, Kamada N, KitazumeMT, Honda H, Oshima Y, et al. Monocyte chemoattrac-
tant protein-1 contributes to gut homeostasis and intestinal inflammation by composition of IL-10-pro-
ducing regulatory macrophage subset. J Immunol 2010; 184:2671–2676. doi: 10.4049/jimmunol.
0804012 PMID: 20107182
48. Sun L, Louie MC, Vannella KM, Wilke CA, LeVine AM, Moore BB, et al. New concepts of IL-10-induced
lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. Am J Physiol Lung Cell Mol
Physiol 2011; 300:341–353.
49. de Mast Q, Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a system-
atic literature review. J Hypertens 2009; 27:1333–40. doi: 10.1097/HJH.0b013e328329bbf4 PMID:
19365285
50. Virzì GM, de Cal M, Day S, Brocca A, Cruz DN, Castellani C, et al. Pro-Apoptotic Effects of Plasma
from Patients with Cardiorenal Syndrome on Human Tubular Cells. Am J Nephrol 2015; 41:474–84 doi:
10.1159/000438459 PMID: 26228789
51. Dawson J, Cockerill G, Choke E, Loftus I, ThompsonMM. Aortic aneurysms as a source of circulating
interleukin-6. Ann N Y Acad Sci 2006; 1085:320–3 PMID: 17182950
52. Azizzadeh A, Sanchez LA, Miller CC 3rd, Marine L, Rubin BG, Safi HJ, et al. Glomerular filtration rate is
a predictor of mortality after endovascular abdominal aortic aneurysm repair. J Vasc Surg 2006; 43:14–
8 PMID: 16414381
53. WangM, Spinetti G, Monticone RE, Zhang J, Wu J, Jiang L, et al. A local proinflammatory signalling
loop facilitates adverse age-associated arterial remodeling. PLoS One 2011; 6:e16653 doi: 10.1371/
journal.pone.0016653 PMID: 21347430
54. Viaene L, Annaert P, de Loor H, Poesen R, Evenepoel P, Meijers B. Albumin is the main plasma bind-
ing protein for indoxyl sulfate and p-cresyl sulfate. Biopharm Drug Dispos 2013; 34:165–75. doi: 10.
1002/bdd.1834 PMID: 23300093
IS Induces Profibrotic Macrophage Differentiation
PLOS ONE | DOI:10.1371/journal.pone.0149276 February 29, 2016 17 / 17
